PF-Atlas › Clinical Trials › NCT05762900
Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
Ultra-fractionated radiation therapy · Phase 2
Registry ID
NCT05762900
Phase
Phase 2
Status
Recruiting
Drug / intervention
Ultra-fractionated radiation therapy
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Start
2022-10-25
Enrollment
65
Locations
1
About this trial
This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05762900 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.